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Abstract
Classical chemotherapeutics, such as cisplatin and its analogues, have been highly successful in 
the clinic, yet improvements can certainly be made, given the significant side effects associated 
with the killing of healthy cells. Recent advances in the field of chemotherapy include the 
development of targeted anticancer agents, compounds that are directed towards a specific 
biomarker of cancer, with the hopes that such targeted therapies might have reduced side effects 
given their greater selectivity. Here we discuss several transition metal complexes that are tailored 
towards various biomolecules associated with cancer. Most notably, the success of rhodium 
metalloinsertors, which specifically bind to nucleic acid base mismatches in DNA, highlight the 
enormous potential of this exciting new strategy.
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Since the discovery of the anticancer properties of cis-dichlorodiammine-platinum(II) 
(cisplatin), the field of medicinal inorganic chemistry has burgeoned.1–5 For many years, the 
field focused on the development of more potent analogues, second and third generation 
derivatives, leading to the FDA approval of two additional cis-platinum(II) complexes, 
carboplatin and oxaliplatin (Figure 1).2,3 Cisplatin and carboplatin, in particular, have been 
highly successful in the treatment of a variety of cancers, including testicular, ovarian, 
cervical, and non-small cell lung cancers.4 However, these treatments are often associated 
with severe side effects and a build-up of resistance. These issues have led researchers to 
focus more recently on the development of novel non-platinum chemotherapeutics.
The rich photophysical and photochemical properties of metal complexes, in addition to 
their basic coordination chemistry, make them ideal scaffolds for a wide variety of 
biological applications. Though the pharmaceutical industry in general has shied away from 
“heavy metal” pharmaceuticals, with the exception of cis-platin and its derivatives, there are 
in fact real opportunities in the development of transition metal pharmaceuticals, given their 
high modularity, ease of synthesis in preparing molecules of complex shapes and 
symmetries, and the ability to monitor their fate within the cell using a variety of 
spectroscopies. In this Comment, we do not intend to carry out an exhaustive review of 
research in this area. Instead, we discuss here illustrative, recent efforts to develop the next 
generation of metal chemotherapeutics. The focus of many laboratories has been earlier in 
the preparation of basically more potent metal complexes that function like cis-platin in 
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coordinating to DNA but are more effective, either because of more optimum uptake 
characteristics, or the inability of lesions formed to be easily detected and repaired. Much 
time and attention have been spent in this arena. However the goal has moved also to the 
design of complexes with a new strategy based upon selectivity, with the preparation of 
transition metal complexes that are more selective than cis-platin owing to a design strategy 
where the complex interacts with a specific biological target found prominently in cancer 
cells.
Cisplatin and its analogues were developed as “classical” chemotherapeutics. These types of 
drugs are meant to interfere with replication and/or the mitotic processes of tumor cells.5 In 
this way, they achieve potency by damaging cancer cells more than healthy cells. While this 
approach has been fruitful, it has been known to cause a litany of side effects, such as 
nephrotoxicity, neurotoxicity, leukopenia, and thrombocytopenia, as well as nausea, 
vomiting, and hair loss.6 For these reasons, research efforts in recent years have shifted 
towards the development of targeted chemotherapy. In “targeted” therapy, a drug is 
developed to target a specific cellular signaling pathway on which cancer cells depend for 
growth, metastasis, or angiogenesis.7 These types of compounds aim to damage cancer cells 
instead of healthy cells. Targeted therapy focuses on the development of selective 
therapeutics, whereas classical therapy has focused on the development of increasingly 
cytotoxic compounds. The next generation of chemotherapeutics has focused on targeting 
biomolecules, including proteins, organelles, and specific DNA lesions (Figure 2).
As an illustration, the high levels of mutagenesis in cancerous cells often lead to 
upregulation and overexpression of proteins, making them attractive candidates for 
targeting. Metal complexes, due to their modular nature and inherent chirality, are uniquely 
able to target selectively these chiral biomolecules. In particular, this approach has been 
applied toward the selective inhibition of kinase activity. Phosphorylation of proteins by 
kinases is a highly important regulatory activity. However, over-phosphorylation of proteins 
is common in many types of cancer.8 In a recent study by Meggers et al., inert metal 
complexes, inspired by the natural product staurosporine and termed octasporines, were 
designed as highly selective kinase inhibitors (Figure 2).9,10 Six complexes were 
synthesized, all containing a ruthenium or iridium center and a bidentate pyridocarbazole 
ligand designed to bind the hinge region of the ATP-binding pocket of the kinase. However, 
the remaining ligands on each complex were designed to make up a unique set of hydrogen-
bonding interactions with the glycine-rich loop of the ATP-binding pockets of six distinct 
kinases (Figure 3).9 In vivo studies have revealed the anti-angiogenic properties of one of 
these types of compounds in zebrafish embryos, exemplifying their potential.10
Whereas the previous example utilized the structural complexity of inert metal complexes, 
the reactive nature of certain metal centers can also be exploited in targeted therapy. 
Proteases play a crucial role in tumorigenesis by suppressing cell-death pathways and 
promoting cell-survival pathways.11 One such protease, cathepsin B, has been targeted by 
ruthenium arene RAPTA compounds (Figure 2).12,13 These compounds were found to 
inhibit cathepsin B protease activity and exhibited selective anti-metastatic activity in 
vivo.13,14 Estrogen receptors such as estrogen receptor α (ERα), which is overexpressed in 
several types of breast cancer, have also been the subject of targeted therapy studies.15 
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Several organometallic analogues of tamoxifen, an antagonist of estrogen receptors, have 
been developed to selectively target ERα (Figure 2).16,17 These complexes have 
demonstrated cytotoxic activity selectively in ERα-positive breast cancer cell lines.16
In addition to protein targeting, the mitochondria can also serve as a valuable target for drug 
design. Mitochondria produce reactive oxygen species as a byproduct of metabolism, and 
they also play a crucial role in the regulation of cell death pathways.18 Targeting 
mitochondria and mitochondrial DNA can induce apoptosis in tumorigenic cells, as was 
recently demonstrated by Lippard and Kelley.19 They constructed a cis-platinum(II) 
complex tethered to a mitochondrial penetrating peptide, which contained alternating 
cationic and lipophilic residues to enhance mitochondrial uptake (Figure 2). This complex 
was shown to localize almost exclusively to mitochondria in several cancer cell lines. 
Moreover, the complex was able to induce apoptosis in cisplatin-resistant ovarian cancer 
cells by damaging mitochondrial DNA.
The proposed mechanism of action of classical platinum-based chemotherapeutics is the 
formation of covalent DNA adducts, followed by cellular processing of these lesions.4 The 
synthesis of new generation classical therapeutics with enhanced DNA binding properties in 
order to increase cytotoxicity has been extensively explored. However, the design and 
synthesis of therapeutics that bind to specific DNA lesions that are more prevalent in cancer 
cells than normal cells may represent a targeted strategy for new chemotherapy. In 
particular, rhodium metalloinsertors (Figure 2) are known to bind mismatches in duplex 
DNA in vitro with high specificity and affinity.20 These complexes, which all bear the 
sterically expansive 5,6-chrysene diimine (chrysi) ligand, bind 80% of DNA mismatches in 
all sequence contexts and preferentially target thermodynamically destabilized mismatches 
over matched base pairs by a factor of over 1000.21,22 The binding mode of these complexes 
to mismatched DNA was structurally characterized and revealed that the chrysi ligand 
inserts into the DNA from the minor groove and ejects both mismatched bases in a binding 
mode termed metalloinsertion (Figure 4).23–26 Ejection of the mismatched bases results in a 
large lesion that is hypothesized to have the potential to be recognized in vivo.
Mismatches in genomic DNA arise naturally as a consequence of replication, but if left 
uncorrected can lead to mutations.27,28 The mismatch repair (MMR) pathway serves as a 
checkpoint to increase the fidelity of DNA replication ~1000 fold.29 Importantly, 
deficiencies in the mismatch repair machinery have been associated with several types of 
cancer, as well, notably, as increased resistance to classical chemotherapeutics such as 
cisplatin.30 Therefore, the development of a targeted therapy for MMR- deficient cancers 
would be invaluable in the clinic. Due to the unique DNA mismatch-binding properties of 
rhodium metalloinsertors, we sought to explore their biological properties in MMR-deficient 
cells. The compounds were initially found to inhibit growth in MMR-deficient colorectal 
cancer cells over MMR-proficient cells, as measured by antibody assays for DNA 
synthesis.31,32 In a follow-up study, it was discovered that metalloinsertors with accelerated 
uptake also exhibited preferential cytotoxicity towards MMR-deficient cells (Figure 4).33
Most recently, a structure-function study was conducted by altering the lipophilicities of the 
non-inserting ligands.34,35 This investigation resulted in the synthesis of a family of 
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mismatch-binding complexes with similar binding affinities and selectivities for DNA 
mismatches, yet drastically different selectivities for MMR-deficient cells. It was discovered 
that more lipophilic complexes did not exhibit the unique cell-selective activities for which 
metalloinsertors are distinguished. However, complexes with more hydrophilic ancillary 
ligands were highly selective for the MMR-deficient cells over MMR-proficient cells. It was 
discovered that nuclear uptake of all metalloinsertors studied was sufficient for mismatch 
binding to genomic DNA. However, significant mitochondrial uptake led to an abolishment 
of their selective targeting of MMR-deficient cells. Most notably, simply substituting a 
hydroxyl group for a methyl group results in dramatic changes in cell-selective activity due 
to drastic changes in the subcellular localization (Figure 5).35 This study supports the notion 
that the unique cell-selective activities of these compounds rises from targeting of 
mismatches in genomic DNA. In an effort to more directly relate the biological activity of 
rhodium metalloinsertors to the MMR-deficiency phenotype, our laboratory has now 
embarked on studies to validate the biological efficacy of these compounds.
All of the cell assay experiments characterizing the in cellulo effects of rhodium 
metalloinsertors had been undertaken on the isogenic cell lines HCT116N and HCT116O. 
The HCT116 parent cell line is a human colorectal carcinoma line deficient in the hMLH1 
gene. This gene encodes for part of the mismatch repair (MMR) machinery; consequently 
this cell line is MMR-deficient. The HCT116N cell line has been transfected with human 
chromosome 3 (ch3), which restores MMR proficiency, while the HCT116O cell line has 
been transfected with human chromosome 2 (ch2), leaving it MMR-deficient.36 In this 
model system, however, the MMR-proficient cells and MMR-deficient cells are generated as 
different clones, and are distinct from the parental cell line. These differences can result in 
changes in chromosome stability or gene expression that are not solely due to MMR 
deficiency. To this end, we engineered NCI-H23 lung adenocarcinoma cells that contain a 
doxycycline-inducible short hairpin RNA (shRNA) that suppresses the expression of the 
mismatch repair gene MLH1. This provides an isogenic cell line system that can be used to 
directly compare MMR-proficient and MMR-deficient cells.37
It was found that these MLH1-deficient cells, which are more resistant to the DNA 
damaging agents doxorubicin, cisplatin, and etoposide, are indeed more sensitive to rhodium 
metalloinsertors (Figure 6).37 These results further validate the biological activity of 
rhodium metalloinsertors, as they have now been shown to exhibit selective biological 
effects across multiple assays and in different systems for comparing MMR deficiency to 
proficiency. Clearly, the strategy of targeting a specific lesion in DNA is a promising 
alternative to the classical approach.
Targeted chemotherapy thus holds the potential to combat the severe side effects and 
acquired resistance associated with classical chemotherapeutics such as cisplatin. Many 
years of study have focused on achieving high potency for metal complex therapeutics. But 
such potency has been achieved. Just as the design of organic chemotherapeutics have 
shifted from potent alkylators and other inhibitors of DNA synthesis to far more tailored, 
subtle reagents, the design of novel metallotherapeutics now requires a targeted approach. 
There has really been a paradigm shift in next generation chemotherapeutic drug design that 
focuses on specifically tailored therapies. The unique reactivity and coordination geometry 
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of metal complexes make them the ideal scaffold for this new tailor-made design of targeted 
therapeutics. The examples discussed in this Comment exemplify the enormous potential of 
this new strategy in transition metal chemotherapy and perhaps lay the groundwork for this 
burgeoning new field.
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Chemical structures of classical platinum-based chemotherapeutics.
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Chemical structures of targeted chemotherapeutics discussed in this Comment: (top, left to 
right) The octasporine complex OS1, a potent inhibitor of the protein kinase GSK3α; 
General architecture of RAPTA cathepsin B inhibitors; Ruthenocene analogues of tamoxifen 
for the selective targeting of ERα; (bottom, left to right) The first generation rhodium 
metalloinsertor, [Rh(bpy)2(chrysi)]3+, selectively binds to mismatched and abasic sites in 
duplex DNA; Structure of mtPt, a cisplatin analogue designed to localize to the 
mitochondria.
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Design of Octasporine complexes as inhibitors of protein kinases (adapted from reference 
9). The pyridocarbazole ligand, common to all complexes, binds to the hinge region (where 
the adenine portion of ATP binds) of the ATP-binding pocket. The remaining A, B, C, and 
D ligands make up a set of hydrogen-bonding interactions with the glycine-rich loop (where 
the ribose triphosphate portion of ATP binds) of the ATP binding pocket, each unique to a 
particular kinase.
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(Left) Crystal structure of [Rh(bpy)2(chrysi)]3+, the first generation metalloinsertor, bound 
to an AC mismatch in duplex DNA. (Right, top) Chemical structure of [Rh(chrysi)(phen)
(DPE)]2+, a later generation metalloinsertor with enhanced selectivity and potency. (Right, 
bottom) Cell-selective cytotoxicity of [Rh(chrysi)(phen)(DPE)]2+, the complex selectively 
kills MMR-deficient (red) cells over MMR-proficient (green) cells.
Weidmann et al. Page 10














Inhibitory effects of [Rh(DPAE)2chrysi]3+ (bottom, left) and [Rh(PrDPA)2chrysi]3+ 
(bottom, center) on cellular proliferation in MMR-deficient HCT116O (red) and MMR-
proficient HCT116N (green) cells as a function of BrdU incorporation during DNA 
synthesis (adapted from reference 35). Percent BrdU incorporation is normalized to that of 
untreated cells. (Bottom, right) Subcellular localization of [Rh(DPAE)2chrysi]3+ (black) and 
[Rh(PrDPA)2chrysi]3+ (hashed). Mitochondrial rhodium content (left axis) has been 
normalized to mitochondrial protein content, and nuclear rhodium content (right axis) is 
expressed as the percentage of cellular rhodium in the nucleus.
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NCI-H23 subclones that were uninduced or induced for MLH1 shRNA were treated with 
either cisplatin (left) or the rhodium metalloinsertor [Rh(chrysi)(phen)(DPE)]2+ (right) 
(adapted from reference 37). Cells were treated at concentrations indicated, and cell viability 
assessed after 4 days using a Cell Titer-Glo assay. IC50 values are shown below the plots.
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